cystic fibrosis Archives

News and Trends 23 Mar 2017

Galapagos Enters Clinical Trials with New Cystic Fibrosis Drug

Galapagos has announced to kick off a Phase I trial with its novel Cystic Fibrosis potentiator GLPG3067, triggering a €7M milestone payment from AbbVie. Galapagos and AbbVie teamed up in 2013, with the aim of developing a triple combination therapy for the treatment of Cystic Fibrosis (CF). Now, Galapagos announced the start of a Phase […]

March 23, 2017 - 2 minutesmins - By Melanie De Almeida

More News! 2 Feb 2017

Galapagos kicks off a Phase IIa trial for Cystic Fibrosis

After Galapagos and AbbVie expanded their collaboration on cystic fibrosis, Galapagos now announces the start of their Phase IIa trial for a novel cystic fibrosis corrector. Since entering their collaboration with AbbVie on cystic fibrosis (CF) in 2013, Galapagos has received almost €40M in milestone payments from AbbVie. Galapagos now announced the start of a Phase […]

February 2, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 5 Jan 2017

Shire sells its RNA platform to a US-based Biotech

Shire has sold its RNA therapy program to a smaller biotech that wants to accelerate the development of products from the platform. The Irish drug giant Shire is giving its MRT program, which includes two mRNA platforms and 12 employees, to US-based RaNA Therapeutics. In exchange, Shire will receive an undisclosed share of equity in the biotech as well […]

January 5, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 Nov 2016

One Step Closer to the First Triple Combination Therapy for Cystic Fibrosis

Galapagos and AbbVie are closer to launching a cystic fibrosis treatment that can outperform the current standards. However, gene therapy and CRISPR might end up taking over in the long term. Despite being abandoned by AbbVie in its rheumatoid arthritis program, Galapagos and the big US pharma expanded their cystic fibrosis partnership in May. The […]

November 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 May 2016

Galapagos and AbbVie expand their Cystic Fibrosis collaboration

Galapagos and AbbVie expand their ongoing collaboration in Cystic Fibrosis. With a growth in the portfolio, Galapagos’ milestones increase from €300M to €520M. The most famous collaboration between AbbVie (US) and Galapagos (Belgium) was perhaps their candidate for rheumatoid arthritis – which hit a reef in September, knocking Galapagos’ stock by 39%. But the less […]

May 2, 2016 - 2 minutesmins - By Denise Neves Gameiro

abbvie galapagos cystic fibrosis glpg1837

News and Trends 17 Feb 2016

After a Deal with Gilead, Galapagos is Still Doing Phase II Trials with AbbVie

Galapagos (Belgium) is moving forward with their cystic fibrosis drug candidate after promising Phase I results – and still in collaboration with AbbVie (US). Curiouser and curiouser… Galapagos is one of the most hotly-discussed Biotechs in Europe, with around 400 employees and historic IPOs on NASDAQ. It is partnered with several big Pharma, like Gilead, AbbVie, Servier (to develop […]

February 17, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 9 Oct 2015

Fixing the ‘Galapagos-AbbVie Disaster’ through a Cystic Fibrosis Therapy

As we reported last Monday, the AbbVie–Galapagos relationship has proven to be rather rocky as of late, with dramatic action down the NASDAQ Stock exchange. After AbbVie pulled out of the Galapagos Rheumatoid Arthritis pipeline, recent success with their joint-research in Cystic Fibrosis (CF) may kick-start the healing process. Their transport protein potentiator therapy for […]

October 9, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 8 Jul 2015

First Success for Imperial Innovations’ Gene Therapy in Cystic Fibrosis

Good news for patients suffering from cystic fibrosis! Imperial Innovations‘ patented gene therapy could improve the patients’ breathing provoking any side effects. An innovation that could help fulfill this unmet medical need. Cystic fibrosis is the most common deadly genetic disease in Europe. Gene deficiency leads to thickening mucus that obstructs lungs and results in […]

July 8, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 19 Aug 2014

ProQR Therapeutics files for a $75m IPO to compete with Vertex Pharmaceuticals

ProQR Therapeutics is a Netherlands-based biotech company focused on developments of drugs to treat genetic disorders. Daniel de Boer, Gerard Platenburg, Dinko Valerio and Henri Termeer (former Genzyme’s CEO) founded the company in May 2012 with the main goal of finding a treatment for cystic fibrosis. ProQR has now expanded to more than 50 employees who are working […]

August 19, 2014 - 3 minutesmins - By Joachim Eeckhout

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

cystic fibrosis

Galapagos Enters Clinical Trials with New Cystic Fibrosis Drug

Galapagos kicks off a Phase IIa trial for Cystic Fibrosis

Shire sells its RNA platform to a US-based Biotech

One Step Closer to the First Triple Combination Therapy for Cystic Fibrosis

Galapagos and AbbVie expand their Cystic Fibrosis collaboration

After a Deal with Gilead, Galapagos is Still Doing Phase II Trials with AbbVie

Fixing the ‘Galapagos-AbbVie Disaster’ through a Cystic Fibrosis Therapy

First Success for Imperial Innovations’ Gene Therapy in Cystic Fibrosis

ProQR Therapeutics files for a $75m IPO to compete with Vertex Pharmaceuticals

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!